share_log

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

EyePoint Pharmaceuticals | 144:拟议出售证券

美股SEC公告 ·  01/24 16:21

Moomoo AI 已提取核心信息

EyePoint Pharmaceuticals Inc officer, DAVID S JONES, is set to sell 34,442 shares of common stock on 01/24/2024, as per the latest SEC filings. The shares, valued at approximately $857,950.22, were acquired on the same day through the exercise of stock options, with payment made in cash to the issuer. This transaction follows a recent history of sales by JONES over the past three months, totaling 35,066 shares for gross proceeds of $795,191.34.
EyePoint Pharmaceuticals Inc officer, DAVID S JONES, is set to sell 34,442 shares of common stock on 01/24/2024, as per the latest SEC filings. The shares, valued at approximately $857,950.22, were acquired on the same day through the exercise of stock options, with payment made in cash to the issuer. This transaction follows a recent history of sales by JONES over the past three months, totaling 35,066 shares for gross proceeds of $795,191.34.
根据美国证券交易委员会的最新文件,EyePoint Pharmicals Inc高管戴维·琼斯定于2024年1月24日出售34,442股普通股。这些股票价值约857,950.22美元,于当天通过行使股票期权收购,并以现金支付给发行人。该交易遵循了琼斯在过去三个月中的近期销售记录,共计35,066股股票,总收益为795,191.34美元。
根据美国证券交易委员会的最新文件,EyePoint Pharmicals Inc高管戴维·琼斯定于2024年1月24日出售34,442股普通股。这些股票价值约857,950.22美元,于当天通过行使股票期权收购,并以现金支付给发行人。该交易遵循了琼斯在过去三个月中的近期销售记录,共计35,066股股票,总收益为795,191.34美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息